French pharmaceutical giant Sanofi SA (LON:0O59) said Monday its Covid-19 vaccine developed in partnership with UK Pharma GlaxoSmithKline Plc (NYSE:GSK) could be ready for roll-out by December.
Sanofi is one of the few global vaccine developers yet to roll out a Covid-19 vaccine, but things could change before the year ends. Sanofi France chairman Olivier Bogillot seemed optimistic in Monday’s interview with France Inter, telling the news outlet that the technology it uses to develop the vaccine “was the most efficient a year ago, before messenger-RNA”.
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
Bigollot expects the vaccine to be used in France and overseas amid a rising number of Covid variants despite the late entry into the market. He said:
“We will have to achieve a very high level of collective immunity with the arrival of the variants”.
Is Sanofi stock a buy in July 2021
From a valuation perspective, Sanofi shares trade at an attractive P/E ratio of just 8.94. The company also pays divided at a compelling yield of 3.75% as of the time of writing.
Analysts expect the Sanofi earnings per share to grow by a whopping 324% this year, making the investment opportunity even more accretive. However, the company’s long-term bottom-line growth is less attractive at an average annual rate of just 7.50% for the next five years. Therefore, although SNY shares trade at an attractive valuation multiple, the expectation for long-term capital gains is low. But the high dividend yield can compensate for the low returns.
Technical overview: my price prediction for SNY stock in Q3 2021
Technically, Sanofi’s share price appears to have pulled back recently. However, the stock is yet to hit oversold conditions, and there is still some room to run below, falling below the 100-day moving average. Therefore, SNY shares could witness more declines before making a significant rebound.
Investors can target extended declines at $50.12 or lower at $48.36. The key resistance levels are $52.80 and $54.27.
Bottom line: the case for shorting SNY shares
Although Sanofi trades at an attractive P/E ratio and pays dividends at a compelling yield, the company’s long-term growth prospects are not exciting. Even this year’s solid EPS growth expectations may not be strong enough to convince investors for the long term.
Furthermore, the current decline seems far from over, leaving room for more downward movement. Therefore, it may be best to short the stock now or wait for the price to fall further before buying SNY shares.
Where to buy right now
To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use: